Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma

Cancer Biology and Therapy

Volumn 8, Issue 24, 2009, Pages 2386-2395

  Gheeya, Jinesh S ^a   Chen, Qing Rong ^a   Benjamin, Christopher D ^a,c   Cheuk, Adam T ^a   Tsang, Patricia ^a   Chung, Joon Yong ^b   Metaferia, Belhu B ^a   Badgett, Thomas C ^a   Johansson, Peter ^a   Wei, Jun S ^a   Hewitt, Stephen M ^b   Khan, Javed ^a  

^a Advanced Technology Center   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

Author keywords

Anti cancer agents; Apoptosis; Chemotherapy; Cucurbitacin I; Drug screening; Neuroblastoma; STAT3

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ALSTERPAULLONE; AMONAFIDE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; BORTEZOMIB; CAMPTOTHECIN; COLCHICINE; CUCURBITACIN; CUCURBITACIN 1; DACTINOMYCIN; DAUNORUBICIN; DIDEMNIN B; DOXORUBICIN; ECHINOMYCIN; ETOPOSIDE; HELENALIN; MAYTANSINE; MITOXANTRONE; PACLITAXEL; PEREZONE; TANESPIMYCIN; TENIPOSIDE; TETRANDRINE; TIOGUANINE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALRUBICIN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; ENZYME INDUCTION; ENZYME INHIBITION; MITOSIS INHIBITION; NEUROBLASTOMA; NEUROBLASTOMA CELL;

EID: 75749154422     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.24.10184     Document Type: Article

References (58)

1. Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL. Infant cancer in the U.S.: histologyspecific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol 1997; 19:428-32.
2. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3:203-16.
3. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369:2106-20.
4. ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Res 2001; 61:679-86.
5. Dam V, Morgan BT, Mazanek P, Hogarty MD. Mutations in PIK3CA are infrequent in neuroblastoma. BMC Cancer 2006; 6:177.
6. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27:289-97.
7. Parsons SK, Neault MW, Lehmann LE, Brennan LL, Eickhoff CE, Kretschmar CS, Diller LR. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 1998; 22:669-74.
8. Pearson AD, Craft AW, Pinkerton CR, Meller ST, Reid MM. High-dose rapid schedule chemotherapy for disseminated neuroblastoma. Eur J Cancer 1992; 28:1654-9.
9. Kushner BH, Cheung NK, Kramer K, Heller G, Jhanwar SC. Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 1998; 16:3880-9.
10. Shi X, Franko B, Frantz C, Amin HM, Lai R. JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. Br J Haematol 2006; 135:26-32.
11. Kuroda H, Sugimoto T, Horii Y, Sawada T. Signaling pathway of ciliary neurotrophic factor in neuroblastoma cell lines. Med Pediatr Oncol 2001; 36:118-21.
12. Ciccarone V, Spengler BA, Meyers MB, Biedler JL, Ross RA. Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res 1989; 49:219-25.
13. Ross RA, Biedler JL, Spengler BA. A role for distinct cell types in determining malignancy in human neuroblastoma cell lines and tumors. Cancer Lett 2003; 197:35-9.
14. Cellai I, Benvenuti S, Luciani P, Galli A, Ceni E, Simi L, et al. Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells. Br J Cancer 2006; 95:879-88.
15. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3:1427-38.
16. Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 1997; 17:146-54.
17. Wolf J, Richardson PG, Schuster M, LeBlanc A, Walters IB, Battleman DS. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin Adv Hematol Oncol 2008; 6:755-60.
18. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003; 9:1145-54.
19. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5:2638-45.
20. Nawrocki ST, Carew JS, Dunner K Jr, Boise LH, Chiao PJ, Huang P, et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005; 65:11510-9.
21. Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL, Koeffler HP. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005; 24:344-54.
22. Armstrong MB, Schumacher KR, Mody R, Yanik GA, Opipari AW Jr, Castle VP. Bortezomib as a therapeutic candidate for neuroblastoma. J Exp Ther Oncol 2008; 7:135-45.
23. Hamner JB, Dickson PV, Sims TL, Zhou J, Spence Y, Ng CY, Davidoff AM. Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma. Surgery 2007; 142:185-91.
24. Deeb D, Gao X, Jiang H, Dulchavsky SA, Gautam SC. Oleanane Triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR. Prostate 2009; 69:851-60.
25. Duan Z, Ames RY, Ryan M, Hornicek FJ, Mankin H, Seiden MV. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. Cancer Chemother Pharmacol 2009; 63:681-9.
26. Liby K, Black CC, Royce DB, Williams CR, Risingsong R, Yore MM, et al. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Mol Cancer Ther 2008; 7:1251-7.
27. Alabran JL, Cheuk A, Liby K, Sporn M, Khan J, Letterio J, Leskov KS. Human neuroblastoma cells rapidly enter cell cycle arrest and apoptosis following exposure to C-28 derivatives of the synthetic triterpenoid CDDO. Cancer Biol Ther 2008; 7:709-17.
28. Becker K, Marchenko ND, Maurice M, Moll UM. Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma. Cell Death Differ 2007; 14:1350-60.
29. Armstrong MB, Bian X, Liu Y, Subramanian C, Ratanaproeksa AB, Shao F, et al. Signaling from p53 to NFkappaB determines the chemotherapy responsiveness of neuroblastoma. Neoplasia 2006; 8:967-77.
30. Zou W, Yue P, Khuri FR, Sun SY. Coupling of endoplasmic reticulum stress to CDDO-Me-induced upregulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation. Cancer Res 2008; 68:7484-92.
31. Gao X, Deeb D, Danyluk A, Media J, Liu Y, Dulchavsky SA, Gautam SC. Immunomodulatory activity of synthetic triterpenoids: inhibition of lymphocyte proliferation, cell-mediated cytotoxicity, and cytokine gene expression through suppression of NFkappaB. Immunopharmacol Immunotoxicol 2008; 30:58-600.
32. Gao X, Deeb D, Jiang H, Liu Y, Dulchavsky SA, Gautam SC. Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NFkappaB and Notch1 signaling. J Neurooncol 2007; 84:147-57.
33. Kang J, Kamal A, Burrows FJ, Evers BM, Chung DH. Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors. Anticancer Res 2006; 26:1903-8.
34. Williams CR, Tabios R, Linehan WM, Neckers L. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J Urol 2007; 178:1528-32.
35. Lyss G, Schmidt TJ, Merfort I, Pahl HL. Helenalin, an anti-inflammatory sesquiterpene lactone from Arnica, selectively inhibits transcription factor NFkappaB. Biol Chem 1997; 378:951-61.
36. Huang PR, Yeh YM, Wang TC. Potent inhibition of human telomerase by helenalin. Cancer Lett 2005; 227:169-74.
37. Jayaprakasam B, Seeram NP, Nair MG. Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. Cancer Lett 2003; 189:11-6.
38. Su Y, Li G, Zhang X, Gu J, Zhang C, Tian Z, Zhang J. JSI-124 inhibits glioblastoma multiforme cell proliferation through G(2)/M cell cycle arrest and apoptosis augment. Cancer Biol Ther 2008; 7:1243-9.
39. Takano S, Gately S, Jiang JB, Brem S. A diaminoantraquinone inhibitor of angiogenesis. J Pharmacol Exp Ther 1994; 271:1027-33.
40. Mao Y, Yu C, Hsieh TS, Nitiss JL, Liu AA, Wang H, Liu LF. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. Biochemistry 1999; 38:10793-800.
41. Iarussi D, Indolfi P, Casale F, Coppolino P, Tedesco MA, Di Tullio MT. Recent advances in the prevention of anthracycline cardiotoxicity in childhood. Curr Med Chem 2001; 8:1649-60.
42. Huang HS, Chiu HF, Lu WC, Yuan CL. Synthesis and antitumor activity of 1,8-diaminoanthraquinone derivatives. Chem Pharm Bull 2005; 53:1136-9.
43. Chiosis G, Lucas B, Huezo H, Solit D, Basso A, Rosen N. Development of purine-scaffold small molecule inhibitors of Hsp90. Curr Cancer Drug Targets 2003; 3:371-6.
44. Schultz C, Link A, Leost M, Zaharevitz DW, Gussio R, Sausville EA, et al. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/ cyclin B inhibition, and in vitro antitumor activity. J Med Chem 1999; 42:2909-19.
45. Hsiang YH, Jiang JB, Liu LF. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs. Mol Pharmacol 1989; 36:371-6.
46. Kitareewan S, Roebuck BD, Demidenko E, Sloboda RD, Dmitrovsky E. Lysosomes and trivalent arsenic treatment in acute promyelocytic leukemia. J Natl Cancer Inst 2007; 99:41-52.
47. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4:349-60.
48. Teicher BA. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 2008; 75:1262-71.
49. Yanagawa T, Noguchi T, Miyachi H, Kobayashi H, Hashimoto Y. Tubulin polymerization inhibitors with a fluorinated phthalimide skeleton derived from thalidomide. Bioorg Med Chem Lett 2006; 16:4748-51.
50. Koba M, Konopa J. Actinomycin D and its mechanisms of action. Postepy Hig Med Dosw 2005; 59:290-8.
51. Marco E, Martin-Santamaria S, Cuevas C, Gago F. Structural basis for the binding of didemnins to human elongation factor eEF1A and rationale for the potent antitumor activity of these marine natural products. J Med Chem 2004; 47:4439-52.
52. 2+ complex on DNA: a new paradigm for the structure of a drug-DNA complex and implications for the structure of the quinolone bacterial gyrase-DNA complex. J Med Chem 1995; 38:408-24.
53. Hartmann JT, Lipp HP. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II-mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf 2006; 29:209-30.
54. Gupta S, Bhattacharyya B. Antimicrotubular drugs binding to vinca domain of tubulin. Mol Cell Biochem 2003; 253:41-7.
55. Lipp HP, Bokemeyer C. The action and toxicity of taxanes. Pharm Unserer Zeit 2005; 34:128-37.
56. Lee JH, Kang GH, Kim KC, Kim KM, Park DI, Choi BT, et al. Tetrandrine-induced cell cycle arrest and apoptosis in A549 human lung carcinoma cells. Int J Oncol 2002; 21:1239-44.
57. Onrust SV, Lamb HM. Valrubicin. Drugs Aging 1999; 15:69-75.
58. Duflos A, Kruczynski A, Barret JM. Novel aspects of natural and modified vinca alkaloids. Curr Med Chem Anticancer Agents 2002; 2:55-70.